Delphi-based Spanish consensus on the use of long-acting growth hormone in pediatric growth hormone deficiency: recommendations from the ConverGHe Working Group.

ABSTRACT:

Background

Long-acting growth hormone (LAGH) formulations have emerged as an alternative to daily recombinant human growth hormone (rhGH) in pediatric growth hormone deficiency (GHD). Although evidence from meta-analyses and randomized trials supports their efficacy and safety, real-life data are still lacking, and therefore clinical guidance on their implementation remains limited.

Objective

To develop expert-based recommendations for the clinical use of LAGH in pediatric GHD within Spain.

Methods

A two-round Delphi approach was used. Based on a literature review, a scientific committee comprised of pediatric endocrinologists developed a questionnaire structured into three domains: (1) Main benefits of LAGH vs. daily rhGH; (2) Candidate profiles for LAGH thera

SUBMITTER: Castro-Feijoo L 

PROVIDER: S-EPMC12711535 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature